Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV–HCV coinfection case
Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir is a highly effective regimen of the direct acting antiviral therapy for chronic hepatitis C virus (HCV) infection , which is approved in Japan. A 31-year-old Japanese man with chronic HCV genotype 1b and HIV-1 infections, who was treatment naïve for both viruses, was administered OBV/PTV/ritonavir (25/150/100 mg) once a day as an initial treatment, without combination antiretroviral therapy (ART) for HIV-1 infection. At baseline, his liver function was normal, CD4+ cell count was 775 cells/μl, serum HCV RNA and plasma HIV RNA were 6.1 log copies/ml and 13 000 copies/ml, respectively. At 4 and 8 weeks, serum HCV RNA was less than 1.2 log and less than 1.2 log copies/ml and plasma HIV RNA decreased to 29 and 240 copies/ml, respectively. Dolutegravir/abacavir/lamivudine administration was initiated at 8 weeks to prevent ART resistance.